key: cord-0806884-fjty15kt authors: Gustavo Bonavita, Andre title: Ac2-26 Mimetic Peptide of Annexin A1 to treat severe COVID-19: a hypothesis date: 2020-10-21 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.110352 sha: b463ef1d2da46a03e950050e49dd76c3076d29ed doc_id: 806884 cord_uid: fjty15kt The Coronavirus Diseases-2019 (COVID-19) pandemic leads many researchers around the world to study the SARS-CoV-s2 infection and pathology to find a treatment for it. This generates a massive production of papers including pre-clinical, clinical and revisions but till now no specific treatment were identified. Meanwhile, like other coronavirus infections, COVID-19 leads to the cytokine storm syndrome resulting in hyperinflammation, exacerbated immune response and multiple organ dysfunctions indicating that drugs that modulate this response, as glucocorticoids could be a treatment option. However glucocorticoids have several side effects or usage limitations. In this sense a drug with anti-inflammatory effects and capable to reduce inflammation but with less after-effects could be a powerful tool to combat COVID-19. Thus the Ac2-26 Mimetic Peptide of Annexin A1 emerges as a possible therapy. The peptide has many anti-inflammatory effects described including the reduction of interleukin (IL)-6, one of the main mediators of cytokine storm syndrome. Therefore the hypothesis to use the Ac2-26 peptide to treat severe COVID-19 will be highlighted in this paper. The COVID-19 caused more than 1 million deaths worldwide being a important heath problem [1] . This drove many research groups to better understand the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) biology and pathology to offer new insights for treatments and development of new therapies. Besides a lot of the patients have a good prognosis there are still some individuals that evolve to severe disease and even death [2] . Death seems to be related with the acute respiratory distress syndrome (ARDS) and multiple-organ failure (MOF) as a consequence of the cytokine storm syndrome (CSS) which was detected in several critical patients with COVID-19 [3, 4] . Zhou and colleagues showed that IL-6 and inflammation are increased in critical patients with COVID-19 [5]. The higher levels of IL-6 seems fundamental to the disease aggravation and development of ARDS and MOF [6] . Hence, drugs that can control inflammation and IL-6 secretion could be a relevant tool to reduce COVID-19 severity and associated deaths [7, 8] . It was observed that treatment for 10 days with the steroid anti-inflammatory dexamethasone was able to reduce death in patients with severe condiction [8] . However it is well know that glucocorticoids have many side effects [9] including the immunosuppressive action that could potentially lead to increase of plasma viral load. It is well described that many anti-inflammatory effects of glucocorticoids are mediated by Annexin-A1 (ANXA1) protein witch act by activation of formyl peptide receptors (FPR) family [10]. The anti-inflammatory effects of ANXA1 can be mimic by it N-terminal domain with 26 amino acid termed Ac2-26 peptide [11] . Herein is presented the many effects of Ac2-26 peptide that support the use of it to treat severe COVID-19. During the acute inflammatory response several pro-inflammatory mediators are produced as well the endogenous anti-inflammatory and pro-resolving mediators [12, 13] . These anti-inflammatory mediators act regulating the inflammation by reducing cell migration, edema, cytokine production as well promoting inflammatory cells apoptosis [14] . One of the anti-inflammatory mediators is a protein regulated by glucocorticoid named annexin-A1 (ANXA1), [28] . Table 1 summarizes the antiinflammatory effects described for the Ac2-26 peptide. In this moment evidence suggests that host immune response contributes to the severity of COVID-19 as well the higher admissions at intensive care unit (ICU) and mortality [43] [44] [45] . In the severe cases of infected patients it was observed an increased plasma concentration of many pro-inflammatory cytokines as TNF- IL-6, IL-8, G-CSF, MCP-1, IP-10, MIP-1 characterizing the CSS and the consequent hyperinflammation and MOF [45] . Recent works suggested that drugs as glucocorticoid, anti-IL-6 antibody (Tocilizumab), IL-1 antagonist (Anakinra) could modulate this extreme host reaction resulting in a better prognostic for severe COVID-19 patients [46] . Recently the RECOVERY trial from the Oxford University showed that treatment with 6 mg of dexamethasone for 10 days reduce the mortality of patients with the severe form of COVID-19 [8]. This result was highly associated the presence of lung inflammation. The use of glucocorticoids was previously suggested to others lung infections (e.g. MERS, SARS, severe influenza and community-acquired pneumonia) however the lack of randomized/controlled trials and the heterogeneity of doses or medical conditions discourage it use [47] [48] [49] [50] . Moreover glucocorticoid is not indicated in patients with comorbidities like Cushing syndrome or non-compensate diabetes mellitus [51, 52] . In this way a drug with similar anti-inflammatory profile but lacking the side effects could be a tool to treat these patients. As mentioned above, the ANXA1 derived peptide Ac2-26 share many antiinflammatory effects of the glucocorticoids including the inhibition of several cytokines production (see Table 1 ). These effects were observed in different preclinical models using in vitro and in vivo experiments. The potent inhibitory effect of Ac2-26 over inflammation indicates that the ANXA1-derived peptide could be relevant to reduce the COVID-19 severity and associated deaths. The increased levels of IL-6 and others mediators of inflammation like IL-1, TNF- triggers the so called cytokine storm syndrome which is closely related with the COVID-19 evolution and seems responsible for 28% of the deaths [3, 6] . The cytokine storm promotes an uncontrolled inflammation with directly lung failure and it inflicts multiorgan damage failure, mostly in cardiac, hepatic and renal systems. In vitro and in vivo studies demonstrated that Ac2-26 peptide was able to reduce inflammation and enrolled mediators in many models where inflammation is relevant and then it was suggested to treat several diseases as allergy, cancer, stroke, sepsis or ischemia [11, 24, 53] . In lungs, Ac2-26 showed protective effects in by reducing inflammation in different conditions [24, 25, 29, 42] suggesting it could have an important paper during COVID-19 treatment. The myocardium damage is also present in patients with severe COVID-19 [54] . In this tissue the Ac2-26 showed a protective effect after ischemia-reperfusion injury [55] . Acute kidney injury rate to 50% of patients in severe COVID-19 being a risk factor for mortality [56] . A work showed that annexin-A1 N-terminal derived-peptide can protect renal tissue against Bothrops moojeni Venom-induced inflammation in rats [32] . Complementary, Ac2-26 showed renal protection against drug-associated inflammation (e.g. tacrolimus or cyclopsporin) or in model of ischemia-reperfusion [57] [58] [59] . Taking together these findings suggest that Ac2-26 could have a relevant protective action on hyperinflammation-driven MOF during COVID-19 and probably reducing severity and death. Other point to mention is that during COVID-16 occurs coagulopathy with increased venous coagulation [60] . Besides there are no evidence of direct action of Ac2-26 on platelet aggregation there are two papers that presented effects of ANXA1 on coagulation. The first work of Kuster and colleagues observed an antiplaque effect of human-recombinant ANXA1 in mice with atherosclerosis [61] . The second described a novel role for ANXA1, the ability to activate anti-thromboinflammatory circuits in cerebral during ischemia-reperfusion [62] . Since many the The author declare have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. IL-6 Reduce production and signaling [30, 32, 36, 37] IL-1 Reduce production and effects on neutrophil migration [28, 32, 36, 38, 39] IL-8 Reduce production [29, 31] Interferon- Reduce production [36, 40] TNF- Reduce production and intracellular activated pathways [28] [29] [30] 36, 41, 42] MCP-1 and Reduce production [28, 42] Mast cell activation Reduce cell degranulation and release of histamine [27] Edema Reduce exudate [27, 29] Pain Reduce pain response [28, 38] NFkB Reduce NFkB activation/translocation [29, 31] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges COVID-19 cytokine storm: The anger of inflammation A novel effect for annexin 1-derived peptide Ac2-26: Reduction of allergic inflammation in the rat Annexin-1 Mimetic Peptide Ac2-26 Suppresses Inflammatory Mediators in LPS-Induced Astrocytes and Ameliorates Pain Hypersensitivity in a Rat Model of Inflammatory Pain Ac2-26, an annexin A1 peptide, attenuates ischemia-reperfusion-induced acute lung injury Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro Ac2-Processes Induced by Bothrops moojeni Venom and the Lys-49 Phospholipase A2 in a Rat Model Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: Effect of lipocortin 1 Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement Annexin A12-26 treatment improves skin heterologous transplantation by modulating inflammation and angiogenesis processes Annexin A1-derived peptide Ac2-26 in a pilocarpine-induced status epilepticus model: Anti-inflammatory and neuroprotective effects Annexin A1 promotes timely resolution of inflammation in murine gout Annexin 1 peptides protect against experimental myocardial ischemiareperfusion: analysis of their mechanism of action An annexin 1 (ANXA1)-derived peptide inhibits prototype antigen-driven human T cell Th1 and Th2 responses in vitro Annexin Peptide Ac2-26 Suppresses TNFα-Induced Inflammatory Responses via Inhibition of Rac1-Dependent NADPH Oxidase in Human Endothelial Cells Annexin A1 mimetic peptide controls the inflammatory and fibrotic effects of silica particles in mice Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections The use of antiinflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China Systematic review of treatment effects Corticosteroid therapy for critically ill patients with middle east respiratory syndrome Corticosteroids as adjunctive therapy in the treatment of influenza: An updated cochrane systematic review and meta-analysis Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess COVID-19 and diabetes mellitus: An unholy interaction of two pandemics Annexin A1 Mimetic Peptide AC2-26 Inhibits Sepsis-induced Cardiomyocyte Apoptosis through LXA4/PI3K/AKT Signaling Pathway Myocardial injury and COVID-19: Possible mechanisms Cardioprotective potential of annexin-A1 mimetics in myocardial infarction COVID-19 and Renal Failure: Challenges in the Delivery of Renal Replacement Therapy Interaction of the anti-inflammatory annexin a1 protein and tacrolimus immunosuppressant in the renal function of rats Annexin A1 protein attenuates cyclosporine-induced renal hemodynamics changes and macrophage infiltration in rats Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats COVID-19 coagulopathy: an in-depth analysis of the coagulation system Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/-Mice on Western Type Diet Novel Role for the AnxA1-Fpr2/ALX Signaling Axis as a Key Regulator of Platelet Function to Promote Resolution of Inflammation The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model Annexins in influenza virus replication and pathogenesis This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior -Brasil (CAPES) -Finance Code 001.